Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2024 | Story André Damons | Photo Supplied
Dr Mampoi Jonas and Prof Jan Du Plessis
Dr Mampoi Jonas, senior lecturer in Paediatric Oncology and Prof Jan Du Plessis, Head of the Paediatric Oncology Unit at the University of the Free State (UFS).

A campaign like Childhood Cancer Awareness Month is vital in creating awareness and educating people about the early signs and symptoms of certain cancers. This can significantly improve the survival rate of young patients. More than 50% of people diagnosed with cancer live for more than five years, and some types of cancer have survival rates as high as 90%.

This is according to Prof Jan Du Plessis, Head of the Paediatric Oncology Unit, and Dr Mampoi Jonas, senior lecturer in Paediatric Oncology, at the University of the Free State (UFS).

“Early diagnosis is crucial because early-stage cancer is more responsive to treatment and less likely to be fatal. Due to the rarity of childhood cancer, many children get misdiagnosed or diagnosed too late with advanced stage disease. The delayed detection and diagnosis diminish the chances of successful treatment.

“Cancer awareness educates families, communities, primary-care nurses and doctors about the early signs and symptoms of certain cancers. When people are aware of these, they are more likely to be on the lookout for them when children present with suspicious clinical symptoms and signs. This also gives parents the confidence to seek help early and even make people better able to support those with the disease once a diagnosis is made,” say the paediatric oncologists.

Recorded incidences on the rise

Though childhood cancer is rare, representing only 1.2% of all cancers worldwide, the recorded incidences are increasing. In the US cancer is the number one cause of death among children, while more than 100 000 children worldwide die because of cancer.

Prof Du Plessis says there are more than 12 major types of childhood cancers and multiple subtypes. The most common types are leukaemia, lymphoma (tumours that begin in the lymph glands), brain tumours, nephroblastoma (cancer of the kidneys) and soft tissue sarcomas. Most cancers in children are thought to develop as a result of mutations in genes that lead to uncontrolled cell growth and eventually cancer.

According to Dr Jonas, most cancers in children are thought to develop because of mutations in genes that lead to uncontrolled cell growth and eventually cancer. Although environmental pollutants have been implicated in some cancers, our experience has been that most paediatric cancers rather occur sporadically.

The reasons for the increase of reported incidence of cancer in children, could be to the increase in population numbers and better awareness of childhood cancers. Another reason might be that more children are being diagnosed who were previously misdiagnosed, explains Prof Du Plessis.

Treatments

Childhood cancers are treated with chemotherapy, surgery and radiation therapy under the care of a paediatric oncologist. Not much can be done about the genetic mutations, but parents can ensure that their children stay safe in the sun (slip, slop, slap campaign – slip on a shirt, slop on some suncream and slap on a hat), get their children vaccinated against HPV infection, help their children stay active and keep a healthy weight and talk to them about smoking.

Prof Du Plessis says the South African paediatric oncology community are currently busy with a few research studies regarding standardising treatment protocols for certain childhood cancers. This is to find out how our children are responding to these protocols and to see if there are different factors affecting the outcomes of South African children. These protocols are based on international treatment protocols with a few adjustments for local circumstances and resources.

They are involved with the Hodgkins lymphoma, neuroblastoma, retinoblastoma, germ cell tumour studies and contributed to a research study evaluating the nutritional status and interventions to improve the nutritional status of local patients. Registrars presented local (Bloemfontein) data at an international conference (SIOP Africa) on hepatoblastomas and osteosarcomas.

“For many childhood cancer may not be a priority or something they would like to think about. Unfortunately for many of my patient’s parents the truth is that the day before their children were diagnosed with cancer, they were also not a cancer parent. However, their lives changed for ever with these four words: ‘Your child has cancer’.

“Childhood cancer is more than chemo and no hair. It is rather about resilience, strength, hope, family, courage, cuddles, and bravery. Your life will be changed for ever if you have ever seen a child fight cancer. Their smiles will make your heart melt and make you realise the importance of the simple things in life,” declare Prof Du Plessis and Dr Jonas.

Early warning signs for parents

The Childhood Cancer Foundation South Africa (CHOC) has a campaign which emphasises the importance of recognising the early warning signs of childhood cancer. They use Siluan’s Early Warning Signs to raise awareness and promote early diagnosis which are:

• S – Seek medical help early for ongoing symptoms
• I – White spot in the eye, new squint, sudden blindness or bulging eyeball.
• L – Lump on the stomach, pelvis, head, arms, legs, testicle, or glands
• U – Unexplained fever present for over two weeks, weight loss, fatigue, pale appearance, easy bruising, and bleeding
• A – Aching bones, joints, back, and easy fractures

• N – Neurological signs, a change in walk, balance or speech, regression, continuous headaches with/without vomiting, and an enlarged head

While these symptoms can be subtle or easily attributed to other causes, it’s important to consult a doctor if they persist or worsen. If you notice any of these symptoms in a child or teen, seek professional medical help promptly. Early detection of cancer saves lives in both children and teens.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept